Clinical Trial Update: Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

View source ↗

Summary

This clinical trial update describes a planned evaluation of triplet therapy with darolutamide plus androgen-deprivation therapy and docetaxel for metastatic ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Darolutamide (Nubeqa) (darolutamide)
• Docetaxel (Taxotere) (docetaxel)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Metastatic Hormone-sensitive Prostate Cancer, Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC) | Status: NOT_YET_RECRUITING